We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+20.89%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$6.13B
AUM Growth
+$563M
Cap. Flow
-$172M
Cap. Flow %
-2.8%
Top 10 Hldgs %
24.72%
Holding
175
New
20
Increased
65
Reduced
40
Closed
23

Top Buys

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$59.7M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$54.7M
3
LXEO icon
Lexeo Therapeutics
LXEO
+$37.3M
4
MNDY icon
monday.com
MNDY
+$32.9M
5
XMTR icon
Xometry
XMTR
+$28.5M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$79.8M
2
EXAS
Exact Sciences
EXAS
+$51.4M
3
SHLS icon
Shoals Technologies Group
SHLS
+$42.6M
4
ASND icon
Ascendis Pharma A/S
ASND
+$39.3M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$39.2M

Sector Composition

Rank Sector Weight
1 Healthcare 39.38%
2 Technology 24.68%
3 Industrials 16.87%
4 Consumer Discretionary 8.76%
5 Communication Services 2.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EGP icon
76
EastGroup Properties
EGP
$11.3B
$25.3M 0.41%
138,030
+71,576
+108% +$12.2M
KROS icon
77
Keros Therapeutics
KROS
$202M
$23.1M 0.38%
580,000
– –
PRVA icon
78
Privia Health
PRVA
$3.01B
$23M 0.38%
1,000,000
– –
ASND icon
79
Ascendis Pharma A/S
ASND
$16.5B
$22.8M 0.37%
180,857
-394,581
-69% -$39.3M
IMGN
80
DELISTED
Immunogen Inc
IMGN
$22.6M 0.37%
763,000
-537,000
-41% -$10.7M
STE icon
81
Steris
STE
$22.5B
$21.7M 0.35%
98,873
-2,602
-3% -$550K
MDB icon
82
MongoDB
MDB
$26.2B
$21.7M 0.35%
52,994
+45,703
+627% +$17.3M
ROL icon
83
Rollins
ROL
$18.5B
$21.4M 0.35%
490,330
+2
+0% +$78
RGEN icon
84
Repligen
RGEN
$7.03B
$21.4M 0.35%
119,000
– –
ALV icon
85
Autoliv
ALV
$9.09B
$21.4M 0.35%
193,906
+185,456
+2,195% +$18.5M
NOVT icon
86
Novanta
NOVT
$4.95B
$21.2M 0.35%
126,020
-8
-0% -$1.17K
HLI icon
87
Houlihan Lokey
HLI
$8.97B
$21M 0.34%
175,269
+25,637
+17% +$2.78M
CERE
88
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$20.8M 0.34%
490,000
– –
INSM icon
89
Insmed
INSM
$22B
$19.7M 0.32%
635,185
– –
SRRK icon
90
Scholar Rock
SRRK
$5.87B
$18.3M 0.3%
+972,733
New +$12.1M
ESI icon
91
Element Solutions
ESI
$8.68B
$18.1M 0.3%
782,325
+98,545
+14% +$1.99M
RARE icon
92
Ultragenyx Pharmaceutical
RARE
$2.56B
$17.2M 0.28%
359,000
– –
BHVN icon
93
Biohaven
BHVN
$2.08B
$17.2M 0.28%
+401,101
New +$12.5M
FANG icon
94
Diamondback Energy
FANG
$56.2B
$17M 0.28%
109,621
-60,082
-35% -$9.42M
KRYS icon
95
Krystal Biotech
KRYS
$10.8B
$16.9M 0.28%
+136,485
New +$15.1M
ALNY icon
96
Alnylam Pharmaceuticals
ALNY
$27.4B
$16.7M 0.27%
+87,000
New +$14.8M
AMLX icon
97
Amylyx Pharmaceuticals
AMLX
$2.31B
$16.4M 0.27%
1,116,837
– –
MSCI icon
98
MSCI
MSCI
$41.9B
$16.4M 0.27%
29,024
-599
-2% -$309K
CMS icon
99
CMS Energy
CMS
$22.7B
$16.2M 0.26%
279,080
-52,278
-16% -$2.92M
PRTA icon
100
Prothena Corp
PRTA
$440M
$16.2M 0.26%
445,155
– –
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q4 2023 Portfolio in Review

As of Q4 2023, Eventide Asset Management held 175 positions worth $6.13B, up 10% from $5.56B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Eventide Asset Management's Q4 2023 filing shows 20 new, 65 increased, 40 reduced and 23 closed positions. Its largest new stake was Lexeo Therapeutics: 3,002,831 shares worth $40.3M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $79.8M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 41% a quarter earlier, followed by Technology and Industrials.

  • Eventide Asset Management's largest Q4 2023 buy was Lexeo Therapeutics: 3,002,831 shares worth $40.3M.
  • Eventide Asset Management added most to Celldex Therapeutics in Q4 2023, an estimated $59.7M increase.
  • Eventide Asset Management's biggest Q4 2023 reduction was Exact Sciences, cutting an estimated $51.4M.
  • Eventide Asset Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $79.8M.
  • Eventide Asset Management's ten largest holdings make up 25% of its $6.13B portfolio in Q4 2023.
  • Eventide Asset Management opened 20 new positions and closed 23 in Q4 2023.
  • Eventide Asset Management's portfolio value rose 10% quarter-over-quarter to $6.13B.

Based on Eventide Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.